Tolerability and User Handling Study of an Autoinjector to Administer 180 microg/0.5 mL Peginterferon alfa-2a (Pegasys, PEG-IFN).

Trial Profile

Tolerability and User Handling Study of an Autoinjector to Administer 180 microg/0.5 mL Peginterferon alfa-2a (Pegasys, PEG-IFN).

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 15 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Apr 2010 Actual initiation date (1 Mar 2010) added as reported by Roche record.
    • 16 Apr 2010 Status changed from not yet recruiting to recruiting as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top